- £688.59m
- £1.21bn
- €1.69bn
- 45
- 44
- 97
- 70
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.88 | ||
| PEG Ratio (f) | 0.49 | ||
| EPS Growth (f) | 32.13% | ||
| Dividend Yield (f) | 1.37% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.65 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 7.8 | ||
| Price to Sales | 0.49 | ||
| EV to EBITDA | 6.6 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.6% | ||
| Return on Equity | 6.49% | ||
| Operating Margin | 4.7% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 1,775.4 | 1,693.6 | 1,869.2 | 1,703.9 | 1,689.2 | 1,780.38 | 1,880.8 | -1.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -39.94 | -15.27 | +49.89 | -23.09 | -30.4 | -4.24 | +32.13 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Renewi plc is a waste-to-product company. The Company is a pure-play recycling company that focuses on extracting value from waste and used materials rather than disposing of them through incineration or landfill. It uses technology to turn waste into useful materials, such as paper, metals, plastics, glass, wood, building materials, compost and water. Its segments include Commercial Waste, Mineralz & Water, Specialities, and Group central services. Commercial Waste segment is engaged in the collection and treatment of commercial waste in the Netherlands and Belgium. Mineralz & Water segment is engaged in the decontamination, stabilization, and re-use of highly contaminated materials to produce certified secondary products for the construction industry in the Netherlands and Belgium. Specialities segment is engaged in processing plants focusing on recycling and diverting specific waste streams. It focuses on its core recycling business in the Netherlands, Belgium, France and Portugal.
Directors
- Bernardus Verwaayen NEC (69)
- Otto De Bont CEO
- Toby Woolrych CFO
- Maarten Buikhuisen CIO
- Baukje Dreimuller GCN
- Marc Den Hartog MDR (49)
- Theo Olijve MDR
- James Priestley MDR
- Mark Thys MDR
- Helen Richardson DHR
- Patrick Deprez OTH
- Bas Ginkel OTH
- Daniel Post OTH
- Philip Griffin-Smith SEC
- Allard Castelein NID
- Neil Hartley NID (55)
- Jolande Sap NID (57)
- Luc Sterckx NID
- Marina Wyatt NID
- Last Annual
- March 31st, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- February 4th, 1982
- Public Since
- October 7th, 1986
- No. of Shareholders
- 1,743
- No. of Employees
- 6,756
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
London Stock Exchange- Shares in Issue
- 80,255,720
- Address
- The Stanley Building, 7 Pancras Square, LONDON, N1C4AG
- Web
- https://www.renewi.com/en/privacy-policy
- Phone
- +44 1908650650
- Contact
- Anne Metz
- Auditors
- BDO LLP
Latest News for RWI
Upcoming Events for RWI
Full Year 2025 Renewi PLC Earnings Release
Similar to RWI
ADVFN
London Stock Exchange
Amcomri
London Stock Exchange
Andrews Sykes
London Stock Exchange
Anexo
London Stock Exchange
Ashtead
London Stock Exchange
FAQ
As of Today at 22:54 UTC, shares in Renewi are trading at 858.00p. This share price information is delayed by 15 minutes.
Shares in Renewi last closed at 858.00p and the price had moved by +51.06% over the past 365 days. In terms of relative price strength the Renewi share price has outperformed the FTSE All Share Index by +45.12% over the past year.
The overall consensus recommendation for Renewi is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Renewi dividend yield is 0.58% based on the trailing twelve month period.
Last year, Renewi paid a total dividend of €0.06, and it currently has a trailing dividend yield of 0.58%. We do not have any data on when Renewi is to next pay dividends.
We do not have data on when Renewi is to next pay dividends. The historic dividend yield on Renewi shares is currently 0.58%.
To buy shares in Renewi you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 858.00p, shares in Renewi had a market capitalisation of £688.59m.
Here are the trading details for Renewi:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: RWI
Based on an overall assessment of its quality, value and momentum Renewi is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Renewi is 865.62p. That is 0.89% above the last closing price of 858.00p.
Analysts covering Renewi currently have a consensus Earnings Per Share (EPS) forecast of €0.64 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Renewi. Over the past six months, its share price has outperformed the FTSE All Share Index by +38.6%.
As of the last closing price of 858.00p, shares in Renewi were trading +17.37% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Renewi PE ratio based on its reported earnings over the past 12 months is 11.88. The shares last closed at 858.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Renewi's management team is headed by:
- Bernardus Verwaayen - NEC
- Otto De Bont - CEO
- Toby Woolrych - CFO
- Maarten Buikhuisen - CIO
- Baukje Dreimuller - GCN
- Marc Den Hartog - MDR
- Theo Olijve - MDR
- James Priestley - MDR
- Mark Thys - MDR
- Helen Richardson - DHR
- Patrick Deprez - OTH
- Bas Ginkel - OTH
- Daniel Post - OTH
- Philip Griffin-Smith - SEC
- Allard Castelein - NID
- Neil Hartley - NID
- Jolande Sap - NID
- Luc Sterckx - NID
- Marina Wyatt - NID